Bronte G - Search Results

1

Predicting efficacy and toxicity in the era of targeted therapy: focus on anti-EGFR and anti-VEGF molecules.

Caraglia M, Santini D, Bronte G, Rizzo S, Sortino G, Rini GB, Di Fede G, Russo A. Caraglia M, et al. Among authors: bronte g. Curr Drug Metab. 2011 Dec;12(10):944-55. doi: 10.2174/138920011798062346. Curr Drug Metab. 2011. PMID: 21787268 Review.

2

Circulating myeloid-derived suppressor cells and survival in prostate cancer patients: systematic review and meta-analysis.

Bronte G, Conteduca V, Landriscina M, Procopio AD. Bronte G, et al. Prostate Cancer Prostatic Dis. 2023 Mar;26(1):41-46. doi: 10.1038/s41391-022-00615-5. Epub 2022 Nov 21. Prostate Cancer Prostatic Dis. 2023. PMID: 36411316 Review.

3

The prognostic effects of circulating myeloid-derived suppressor cells in non-small cell lung cancer: systematic review and meta-analysis.

Bronte G, Calabrò L, Olivieri F, Procopio AD, Crinò L. Bronte G, et al. Clin Exp Med. 2023 Sep;23(5):1551-1561. doi: 10.1007/s10238-022-00946-6. Epub 2022 Nov 19. Clin Exp Med. 2023. PMID: 36401744 Free PMC article. Review.

4

Sex steroids, carcinogenesis, and cancer progression.

Castagnetta L, Granata OM, Cocciadiferro L, Saetta A, Polito L, Bronte G, Rizzo S, Campisi I, Agostara B, Carruba G. Castagnetta L, et al. Among authors: bronte g. Ann N Y Acad Sci. 2004 Dec;1028:233-46. doi: 10.1196/annals.1321.028. Ann N Y Acad Sci. 2004. PMID: 15650249 Review.

5

Bortezomib: a new pro-apoptotic agent in cancer treatment.

Russo A, Bronte G, Fulfaro F, Cicero G, Adamo V, Gebbia N, Rizzo S. Russo A, et al. Among authors: bronte g. Curr Cancer Drug Targets. 2010 Feb;10(1):55-67. doi: 10.2174/156800910790980250. Curr Cancer Drug Targets. 2010. PMID: 20088794

6

Anti-endothelin drugs in solid tumors.

Russo A, Bronte G, Rizzo S, Fanale D, Di Gaudio F, Gebbia N, Bazan V. Russo A, et al. Among authors: bronte g. Expert Opin Emerg Drugs. 2010 Mar;15(1):27-40. doi: 10.1517/14728210903571667. Expert Opin Emerg Drugs. 2010. PMID: 20102289 Free article. Review.

7

The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway.

Russo A, Rizzo S, Bronte G, Silvestris N, Colucci G, Gebbia N, Bazan V, Fulfaro F. Russo A, et al. Among authors: bronte g. Oncology. 2009;77 Suppl 1:57-68. doi: 10.1159/000258497. Epub 2010 Feb 2. Oncology. 2009. PMID: 20130433 Review.

8

Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma.

Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C, Santini D, Bazan V, Colucci G, Gebbia N, Russo A. Bronte G, et al. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S21-9. doi: 10.1016/S0305-7372(10)70016-5. Cancer Treat Rev. 2010. PMID: 21129606 Review.

9

Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F, Russo A. Rizzo S, et al. Among authors: bronte g. Cancer Treat Rev. 2010 Nov;36 Suppl 3:S56-61. doi: 10.1016/S0305-7372(10)70021-9. Cancer Treat Rev. 2010. PMID: 21129611 Review.

10

EGFR genomic alterations in cancer: prognostic and predictive values.

Bronte G, Terrasi M, Rizzo S, Sivestris N, Ficorella C, Cajozzo M, Di Gaudio F, Gulotta G, Siragusa S, Gebbia N, Russo A. Bronte G, et al. Front Biosci (Elite Ed). 2011 Jun 1;3(3):879-87. doi: 10.2741/e296. Front Biosci (Elite Ed). 2011. PMID: 21622099 Free article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

113 results

Search Page